Ultragenyx Pharmaceutical Inc. — Cyborg Score 6/10
Mixed
Biopharmaceutical - Rare and Ultra-Rare Genetic Disease Therapeutics
Strategic Profile
Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. The company's advancing late-stage pipeline, successful product launches, and gene therapy innovation position it for diversified growth and improved profitability.
Cyborg Score Rationale
Ultragenyx positions itself as a diversified rare disease company with four approved products generating approximately $670 million in annual revenue, but recent Phase 3 failure of setrusumab highlights a core risk that biomarker success does not guarantee clinical benefit. The company burned roughly $446 million in the first nine months of 2025, implying an annualized ~$600 million burn against ~$735 million in cash—about 1.2 years of runway.
Top Insights
February 2026: FDA acceptance and priority review of DTX401 AAV gene therapy BLA for Glycogen Storage Disease Type Ia
Company faces pivotal 2026 defined by two gene therapy PDUFA decisions (UX111 for Sanfilippo A and DTX401 for GSDIa in Q3 2026) and Phase 3 data for GTX-102 in Angelman syndrome in H2 2026
Crysvita projected to generate $500-520 million in 2026 revenue; Dojolvi forecasted at $100-110 million
Company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs across bone, endocrine, metabolic, muscle and CNS diseases
Named Competitors
Pompe Disease/Lysosomal Storage Disease Therapies — Gene therapies and enzyme replacement therapies for rare genetic diseases